CBU
DFTX

CIBC Bancorp USA’s Definium Therapeutics DFTX Stock Holding History

CIBC Bancorp USA’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$363K Buy
+7,711
New +$191K ﹤0.01% 1443

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

CIBC Bancorp USA's DFTX Position: Q2 2026 in Review

CIBC Bancorp USA opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 7,711 shares worth $363K. The stake represents ﹤0.01% of the portfolio and ranks #1443 among its holdings.

340 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • CIBC Bancorp USA held 7,711 shares of Definium Therapeutics worth $363K as of Q2 2026.
  • Definium Therapeutics was a new CIBC Bancorp USA position in Q2 2026.
  • Definium Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1443 holding.
  • 340 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.